Seres Therapeutics, Inc.MCRBNASDAQ
Loading
Year-over-year revenue growth rate
5Y CAGR
-53.5%/yr
Long-term compound
Percentile
P77
Within normal range
vs 5Y Ago
0x
Contraction
Streak
1 qtr
Consecutive growthDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 24.79% |
| Q3 2025 | 0.00% |
| Q2 2025 | 0.00% |
| Q1 2025 | 0.00% |
| Q4 2024 | 0.00% |
| Q3 2024 | 0.00% |
| Q2 2024 | 0.00% |
| Q1 2024 | -100.00% |
| Q4 2023 | 0.00% |
| Q3 2023 | -100.00% |
| Q2 2023 | 24328.54% |
| Q1 2023 | -153.54% |
| Q4 2022 | -71.69% |
| Q3 2022 | 183.22% |
| Q2 2022 | -18.55% |
| Q1 2022 | -79.32% |
| Q4 2021 | -94.30% |
| Q3 2021 | 2307.85% |
| Q2 2021 | -7.96% |
| Q1 2021 | -67.44% |
| Q4 2020 | 1139.52% |
| Q3 2020 | -76.56% |
| Q2 2020 | -26.18% |
| Q1 2020 | 7.44% |
| Q4 2019 | 8.41% |
| Q3 2019 | -43.89% |
| Q2 2019 | 71.17% |
| Q1 2019 | -31.12% |
| Q4 2018 | 17.38% |
| Q3 2018 | 96.34% |
| Q2 2018 | 16.14% |
| Q1 2018 | 29.94% |
| Q4 2017 | -86.72% |
| Q3 2017 | 663.60% |
| Q2 2017 | -0.03% |
| Q1 2017 | -0.69% |
| Q4 2016 | -76.67% |
| Q3 2016 | 333.26% |
| Q2 2016 | 10.85% |
| Q1 2016 | 0.00% |